Vilija G. Jokubaitis
Vilija G. Jokubaitis
Senior Research Fellow, Neuroimmunology Genomics and Prognostics Group Head, Monash University
Verified email at
TitleCited byYear
Geographical variations in sex ratio trends over time in multiple sclerosis
M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ...
PLOS one 7 (10), e48078, 2012
Fingolimod after natalizumab and the risk of short-term relapse
VG Jokubaitis, V Li, T Kalincik, G Izquierdo, S Hodgkinson, R Alroughani, ...
Neurology 82 (14), 1204-1211, 2014
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ...
Annals of neurology 77 (3), 425-435, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis
A He, T Spelman, V Jokubaitis, E Havrdova, D Horakova, M Trojano, ...
JAMA neurology 72 (4), 405-413, 2015
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
T Kalincik, V Vivek, V Jokubaitis, J Lechner-Scott, M Trojano, G Izquierdo, ...
Brain 136 (12), 3609-3617, 2013
Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination
MD Binder, HS Cate, AL Prieto, D Kemper, H Butzkueven, MM Gresle, ...
Journal of Neuroscience 28 (20), 5195-5206, 2008
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ...
The Lancet Neurology 16 (4), 271-281, 2017
Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis
VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ...
Annals of neurology 80 (1), 89-100, 2016
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
Defining reliable disability outcomes in multiple sclerosis
T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ...
Brain 138 (11), 3287-3298, 2015
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude
J Lechner-Scott, B Spencer, T De Malmanche, J Attia, M FitzGerald, ...
Multiple Sclerosis Journal 18 (7), 974-982, 2012
Risk of relapse phenotype recurrence in multiple sclerosis
T Kalincik, K Buzzard, V Jokubaitis, M Trojano, P Duquette, G Izquierdo, ...
Multiple Sclerosis Journal 20 (11), 1511-1522, 2014
Predictors of disability worsening in clinically isolated syndrome
VG Jokubaitis, T Spelman, T Kalincik, G Izquierdo, F Grand'Maison, ...
Annals of clinical and translational neurology 2 (5), 479-491, 2015
The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform
VG Jokubaitis, T Spelman, J Lechner-Scott, M Barnett, C Shaw, S Vucic, ...
PloS one 8 (3), e59694, 2013
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry
S Hughes, T Spelman, M Trojano, A Lugaresi, G Izquierdo, ...
J Neurol Neurosurg Psychiatry 83 (3), 305-310, 2012
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis
T Kalincik, V Jokubaitis, G Izquierdo, P Duquette, M Girard, P Grammond, ...
Multiple Sclerosis Journal 21 (9), 1159-1171, 2015
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome
C Meyniel, T Spelman, VG Jokubaitis, M Trojano, G Izquierdo, ...
PloS one 7 (6), e38661, 2012
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis
T Kalincik, T Spelman, M Trojano, P Duquette, G Izquierdo, P Grammond, ...
PLoS One 8 (5), e63480, 2013
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
T Kalincik, A Manouchehrinia, L Sobisek, V Jokubaitis, T Spelman, ...
Brain 140 (9), 2426-2443, 2017
Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanism
MM Gresle, E Alexandrou, Q Wu, G Egan, V Jokubaitis, M Ayers, A Jonas, ...
PLoS One 7 (10), e47379, 2012
The system can't perform the operation now. Try again later.
Articles 1–20